BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target lowered by Morgan Stanley from $124.00 to $122.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price target would indicate a potential upside of 119.00% from the stock’s previous close.
BMRN has been the topic of a number of other reports. Raymond James Financial raised BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 price objective on the stock in a report on Monday, October 12th. Piper Sandler upped their price objective on BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, September 1st. Barclays boosted their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $86.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday. Finally, Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $88.60.
Check Out Our Latest Report on BioMarin Pharmaceutical
BioMarin Pharmaceutical Price Performance
Shares of BioMarin Pharmaceutical stock traded down $0.73 during trading on Wednesday, hitting $55.71. 598,027 shares of the company’s stock traded hands, compared to its average volume of 2,092,969. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The firm’s fifty day moving average price is $62.46 and its 200 day moving average price is $58.67. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a market cap of $10.78 billion, a PE ratio of 150.63, a PEG ratio of 0.38 and a beta of 0.22.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same quarter in the prior year, the business posted $1.44 earnings per share. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts forecast that BioMarin Pharmaceutical will post 4.10 earnings per share for the current year.
Institutional Trading of BioMarin Pharmaceutical
Hedge funds and other institutional investors have recently made changes to their positions in the business. Quadrant Capital Group LLC acquired a new position in BioMarin Pharmaceutical during the 3rd quarter worth about $564,000. Nisa Investment Advisors LLC grew its holdings in BioMarin Pharmaceutical by 13.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 4,659 shares of the biotechnology company’s stock worth $280,000 after acquiring an additional 546 shares during the last quarter. Secure Asset Management LLC grew its holdings in BioMarin Pharmaceutical by 3.0% during the 3rd quarter. Secure Asset Management LLC now owns 80,592 shares of the biotechnology company’s stock worth $4,835,000 after acquiring an additional 2,384 shares during the last quarter. Mather Group LLC. grew its holdings in BioMarin Pharmaceutical by 71.0% during the 3rd quarter. Mather Group LLC. now owns 2,337 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 970 shares during the last quarter. Finally, Sanders Morris Harris LLC acquired a new stake in BioMarin Pharmaceutical in the 3rd quarter valued at about $240,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.
BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.
See Also
- Five stocks we like better than BioMarin Pharmaceutical
- Steel Dynamics Eyes New Highs Despite Earnings Miss
- SpaceX Earnings Launch: High Margins Fund AI Ambitions
- 2 Steel Giants Just Reported Earnings—and Told Very Different Stories
- Swiping to Record Highs: Why Visa Remains a Fortress
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
